Reunion Neuroscience - REUN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$15.50
  • Forecasted Upside: 1,465.66%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
C$0.99
▼ -0.05 (-4.81%)

This chart shows the closing price for REUN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Reunion Neuroscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REUN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REUN

Analyst Price Target is C$15.50
▲ +1,465.66% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Reunion Neuroscience in the last 3 months. The average price target is C$15.50, with a high forecast of C$20.00 and a low forecast of C$11.00. The average price target represents a 1,465.66% upside from the last price of C$0.99.

This chart shows the closing price for REUN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Reunion Neuroscience.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/15/2023Stifel NicolausDowngradeSpeculative Buy ➝ Hold
1/19/2023HC WainwrightReiterated RatingBuyC$20.00
12/16/2022Roth CapitalInitiated CoverageBuyC$11.00
(Data available from 3/26/2018 forward)

News Sentiment Rating

-0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/26/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Reunion Neuroscience logo
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: C$0.99
Low: C$0.98
High: C$1.04

50 Day Range

MA: C$1.50
Low: C$0.99
High: C$1.92

52 Week Range

Now: C$0.99
Low: C$0.98
High: C$9.70

Volume

7,600 shs

Average Volume

8,634 shs

Market Capitalization

C$11.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Reunion Neuroscience?

The following equities research analysts have issued stock ratings on Reunion Neuroscience in the last twelve months: HC Wainwright, Roth Capital, and Stifel Nicolaus.
View the latest analyst ratings for REUN.

What is the current price target for Reunion Neuroscience?

2 Wall Street analysts have set twelve-month price targets for Reunion Neuroscience in the last year. Their average twelve-month price target is C$15.50, suggesting a possible upside of 1,465.7%. HC Wainwright has the highest price target set, predicting REUN will reach C$20.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of C$11.00 for Reunion Neuroscience in the next year.
View the latest price targets for REUN.

What is the current consensus analyst rating for Reunion Neuroscience?

Reunion Neuroscience currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe REUN will outperform the market and that investors should add to their positions of Reunion Neuroscience.
View the latest ratings for REUN.

What other companies compete with Reunion Neuroscience?